Association between an endoglin gene polymorphism and systemic sclerosis-related pulmonary arterial hypertension

Rheumatology

Volumn 46, Issue 4, 2007, Pages 622-625

  Wipff, J ^a,b   Kahan, A ^a   Hachulla, E ^c   Sibilia, J ^d   Cabane, J ^e   Meyer, O ^a   Mouthon, L ^a   Guillevin, L ^a   Junien, C ^b   Boileau, C ^b,f   Allanore, Yannick ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c UNIV LILLE   (France)

^d UNIVERSITÉ DE STRASBOURG   (France)

^e HÔPITAL SAINT ANTOINE   (France)

^f HÔPITAL AMBROISE PARÉ   (France)

Author keywords

Endoglin; Gene; Pulmonary arterial hypertension; Systemic sclerosis; TGF

Indexed keywords

ENDOGLIN; GENOMIC DNA;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA DETERMINATION; DNA POLYMORPHISM; DNA SEQUENCE; FEMALE; FLUORESCENCE ANALYSIS; GENE FREQUENCY; GENE INSERTION; GENETIC ASSOCIATION; GENETIC CODE; GENOTYPE; HETEROZYGOTE; HUMAN; HUMAN CELL; INTRON; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; OSTEOARTHRITIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SYSTEMIC SCLEROSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; BASE SEQUENCE; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; POLYMORPHISM, GENETIC; RECEPTORS, CELL SURFACE; SCLERODERMA, SYSTEMIC;

EID: 34047123228     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kel378     Document Type: Article

References (23)

1. Steen VD, Medsger TA,Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000;43:2437-44.
2. Kahaleh BM. Vascular involvement in systemic sclerosis. Clin Exp Rheumatol 2004;22(Suppl 33):S19-23.
3. Fisher MR, Mathai SC, Champion HC et al. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum 2006;54:3043-50.
4. MacGregor AJ, Canavan R, Knight C et al. Pulmonary hypertension in systemic sclerosis: Risk factors for progression and consequences for survival. Rheumatology 2001;40:453-9.
5. Rubin LJ, Badesch DB. Evaluation and management of the patient with pulmonary arterial hypertension. Ann Intern Med 2005;143: 282-92.
6. Assassi S, Tan FK. Genetics of scleroderma: Update on single nucleotide polymorphism analysis and microarrays. Curr Opin Rheumatol 2005;17:761-7.
7. Arnett FC, Cho M, Chatterjee S et al. Familial occurrence frequencies and relative risk for systemic sclerosis (scleroderma) in three United States cohort. Arthritis Rheum 2001;44:1359-62.
8. Lebrin F, Deckers M, Bertolino P, Ten Dijke P. TGF-beta receptor function in the endothelium. Cardiovasc Res 2005; 65:599-608.
9. Shovlin CL, Guttmacher AE, Buscarini E et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 2000;91:66-8.
10. Paquet ME, Pece-Barbara N, Vera S et al. Analysis of several endoglin mutants reveals no endogenous mature or secreted protein capable of interfering with normal endoglin function. Hum Mol Genet 2001;10:1347-57.
11. Fernandez A, Sanz-Rodriguez F, Zarrabeitia R et al. Mutation study of Spanish patients with hereditary hemorrhagic telangiectasia and expression analysis of Endoglin and ALK1. Hum Mutat 2006;27:295.
12. Takenaka K, Sakai H, Yamakawa H et al. Polymorphism of the endoglin gene in patients with intracranial saccular aneurysms. J Neurosurg 1999;90:935-8.
13. Krex D, Ziegler A, Schackert HK, Schackert G. Lack of association between endoglin intron 7 insertion polymorphism and intracranial aneurysms in a white population: Evidence of racial/ethnic differences. Stroke 2001;32:2689-94.
14. Leroy EC, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J Rheumatol 1988; 15:202-5.
15. Altman R, Asch E, Bloch D et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 1986;29:1039-49.
16. Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guideline. Chest 2004; 125(Suppl):1S-92S.
17. Matucci Cerinic M, D'Angelo S, Denton C, Vlachoyannopoulos P, Silver R. Assessment of lung involvement. Clin Exp Rheumatol 2003;21(Suppl 29):S19.
18. Mukerjee D, St George D, Knight C et al. Prevalence and outcome in systemic sclerosis associated pulmonary hypertension: Application of a registry approach. Ann Rheum Dis 2003;62:1088-93.
19. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351:1425-36.
20. Machado RD, Aldred MA, James V et al. Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension. Hum Mutat 2006;27:121-32.
21. Harrison RE, Flanagan JA, Sankelo M et al. Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia. J Med Genet 2003;40:865-71.
22. Chaouat A, Coulet F, Favre C et al. Endoglin germline mutation in a patient with hereditary haemorrhagic telangiectasia and dexfenfluramine associated pulmonary arterial hypertension. Thorax 2004;59:446-8.
23. Harrison RE, Berger R, Haworth SG et al. Transforming growth factor-beta receptor mutations and pulmonary arterial hypertension in childhood. Circulation 2005;111:435-41.